Dexcom Inc (DXCM)

$80.00 -1.01 (-1.25%)
Market Cap 31.76B
Revenue (ttm) 4.03B
Net Income (ttm) 576.20M
EPS (ttm) N/A
PE Ratio 49.59
Forward PE 39.91
Profit Margin 14.29%
Debt to Equity Ratio 0.55
Volume 5,238,800
Avg Vol 3,825,486
Day's Range N/A - N/A
Shares Out 392.11M
Stochastic %K 5%
Beta 1.46
Analysts Strong Sell
Price Target $99.60

Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized thir...

Industry: Medical Devices
Sector: Healthcare
Phone: 858 200 0200
Address:
6340 Sequence Drive, San Diego, United States
Tomyw
Tomyw Jun. 20 at 7:31 PM
$DXCM https://youtu.be/mwHurP6XObw
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 6:18 PM
🚀 $DXCM shares have gained 18.6% QTD, outperforming the industry decline — what's supporting the momentum? 🔹 Record new patient growth & strategic initiatives 🔹 Expansion in reimbursement coverage for non-insulin T2D 🔹 Launch of 15-Day G7 system & strong commercial execution Discover the full story here 👉 https://www.zacks.com/commentary/2519590/dxcms-access-gains-and-operational-strength-offset-margin-pressures?cid=sm-stocktwits-2-2519590-body&ADID=SYND_STOCKTWITS_TWEET_2_2519590_BODY
0 · Reply
Chrisdamelio
Chrisdamelio Jun. 20 at 5:31 PM
$DXCM should be at 100. This is bologna
1 · Reply
Chrisdamelio
Chrisdamelio Jun. 20 at 5:12 PM
$DXCM come on this is no brainer. Why does it keep going down.
1 · Reply
Chrisdamelio
Chrisdamelio Jun. 20 at 5:12 PM
$DXCM
0 · Reply
roejohn
roejohn Jun. 20 at 3:08 PM
$DXCM Dexcom did its job while it was technologically OK but now it is passé. can you imagine their product actually it’s interference with acetaminophen a common over-the-counter item, vitamin C and who knows what other OTC products are problem with Dexcom ? There are just too many contraindications with Dexcom versus the newest technology by $SENS , Eversense 365 is the hottest product to accurately monitor glucose and ketones and may be used with a pump !! check it out
2 · Reply
clan
clan Jun. 20 at 12:52 PM
$DXCM should partner with $MNKD for best Time In Range [TIR].
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 12:22 PM
$DXCM’s patient growth is surging — but is it enough? Record Type 2 diabetes access gains and strong operations are driving growth, but margin pressure and FDA scrutiny are big headwinds. Full breakdown here 👉 https://www.zacks.com/stock/news/2519590/dxcms-access-gains-and-operational-strength-offset-margin-pressures?cid=sm-stocktwits-2-2519590-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2519590_TEASER
0 · Reply
Tomyw
Tomyw Jun. 19 at 11:56 PM
$DXCM …… https://www.eversensecgm.com/eversense-365/?utm_source=facebook&utm_medium=paidsocial&utm_campaign=conversion_prospectingworkableleads_365_dtc_us&utm_content=product_allfeatures_imagetext_1v36_insulin&utm_term=lal_highrated_crm&fbclid=IwQ0xDSwLBgndleHRuA2FlbQEwAGFkaWQBqyI4CuyXdgEeAM78zyw1UFI5dMhHwSzbuuS6XEMGLzsbY3IjyZKF3qY8o4g5d6AlM0MIY9k_aem_4_pPEwsrHC7xgpK8JuekHg&utm_id=120212428326440502 …….
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 19 at 5:39 PM
$SANA There is no way $LLY $NVO $DXCM $PODD are going to allow us to disrupt T1D treatments out of existence without participation. Once again ask your favorite AI what the HIP platform can be applied too! If we have to actually throw the possibilities of cures out in the public domain to force big pharma to partner and license so be it. But there is no way the company can make it through clinical trials to approval in its current form for anything. Go look up the process, typically 1000 patients over years, with some exceptions for gene therapies, rare diseases, the number of beneficiaries and efficacy can speed it up. We’d be bankrupt, bought off the scrap heap. Better to offer HIP, a working MSCB and targeted delivery tech, all of which we have or are developing than to actually make cures and incur the wrath of the big pharma machinery!
1 · Reply
Latest News on DXCM
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025

Jun 18, 2025, 8:30 AM EDT - 3 days ago

Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025

Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders

Jun 10, 2025, 2:06 PM EDT - 10 days ago

Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders

Jefferies' high conviction US stocks for the summer: Nvidia among top picks

Jun 4, 2025, 1:36 PM EDT - 17 days ago

Jefferies' high conviction US stocks for the summer: Nvidia among top picks

COF NVDA

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

May 13, 2025, 8:30 AM EDT - 5 weeks ago

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure

May 9, 2025, 11:00 AM EDT - 6 weeks ago

DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure

DexCom: Growth Is Reaccelerating But Don't Ignore The Risks

May 5, 2025, 4:34 AM EDT - 6 weeks ago

DexCom: Growth Is Reaccelerating But Don't Ignore The Risks

Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism

May 2, 2025, 1:43 PM EDT - 7 weeks ago

Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism

META ON

Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.

May 2, 2025, 11:53 AM EDT - 7 weeks ago

Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.

DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:04 PM EDT - 7 weeks ago

DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript

Dexcom beats quarterly sales estimates, reiterates annual forecast

May 1, 2025, 4:54 PM EDT - 7 weeks ago

Dexcom beats quarterly sales estimates, reiterates annual forecast

Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

May 1, 2025, 4:02 PM EDT - 7 weeks ago

Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

Apr 30, 2025, 4:12 PM EDT - 7 weeks ago

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

ABBV ABT GSK JNJ LLY MRK NVS

Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs

Apr 16, 2025, 12:51 PM EDT - 2 months ago

Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs

JNJ LLY

FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch

Apr 10, 2025, 1:28 PM EDT - 2 months ago

FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch

DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance

Apr 10, 2025, 11:34 AM EDT - 2 months ago

DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

Apr 10, 2025, 8:30 AM EDT - 2 months ago

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

Apr 3, 2025, 8:30 AM EDT - 2 months ago

Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

Mar 31, 2025, 5:02 PM EDT - 2 months ago

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

DAL BBY CCL CEG CZR DECK EPAM

Dexcom Appoints Jon Coleman as Chief Commercial Officer

Mar 25, 2025, 4:05 PM EDT - 3 months ago

Dexcom Appoints Jon Coleman as Chief Commercial Officer

Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom

Mar 25, 2025, 11:50 AM EDT - 3 months ago

Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care

Mar 19, 2025, 4:00 AM EDT - 3 months ago

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care

History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now

Mar 14, 2025, 7:00 AM EDT - 3 months ago

History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now

AMZN ASML BAM CGNX KFRC LCII MAN

Dexcom Appoints Renée Galá to Board of Directors

Mar 10, 2025, 8:30 AM EDT - 3 months ago

Dexcom Appoints Renée Galá to Board of Directors

Dexcom receives FDA warning letter for two U.S. manufacturing facilities

Mar 7, 2025, 5:52 PM EST - 3 months ago

Dexcom receives FDA warning letter for two U.S. manufacturing facilities

DexCom Gets FDA Warning Letter After Inspections of Facilities

Mar 7, 2025, 5:33 PM EST - 3 months ago

DexCom Gets FDA Warning Letter After Inspections of Facilities

DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)

Mar 4, 2025, 1:13 PM EST - 3 months ago

DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)

Dexcom Announces Upcoming Conference Presentation

Feb 27, 2025, 8:30 AM EST - 4 months ago

Dexcom Announces Upcoming Conference Presentation

Quality Key in Volatile Market, NFLX & DXCM Value Plays

Feb 21, 2025, 3:48 PM EST - 4 months ago

Quality Key in Volatile Market, NFLX & DXCM Value Plays

NFLX

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

Feb 14, 2025, 3:04 PM EST - 4 months ago

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

DexCom Analysts Increase Their Forecasts After Q4 Earnings

Feb 14, 2025, 9:22 AM EST - 4 months ago

DexCom Analysts Increase Their Forecasts After Q4 Earnings

DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 9:33 PM EST - 4 months ago

DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript

Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast

Feb 13, 2025, 5:09 PM EST - 4 months ago

Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast

Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 13, 2025, 4:02 PM EST - 4 months ago

Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.

Jan 30, 2025, 8:30 AM EST - 5 months ago

Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

Jan 17, 2025, 4:43 PM EST - 5 months ago

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Jan 14, 2025, 4:31 PM EST - 5 months ago

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

AMZN LLY GSK JNJ MRNA NVDA TDOC

Dexcom forecasts 2025 revenue mostly in-line with expectations

Jan 13, 2025, 7:43 AM EST - 5 months ago

Dexcom forecasts 2025 revenue mostly in-line with expectations

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

Jan 13, 2025, 7:30 AM EST - 5 months ago

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:30 AM EST - 5 months ago

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

Dec 24, 2024, 8:00 AM EST - 6 months ago

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

DOCS GDRX HIMS OSCR PGNY TDOC TEM

DexCom, Abbott Agree to Settlement in Patent Litigation

Dec 23, 2024, 4:56 PM EST - 6 months ago

DexCom, Abbott Agree to Settlement in Patent Litigation

ABT

Abbott and DexCom settle glucose monitor patent disputes

Dec 23, 2024, 4:17 PM EST - 6 months ago

Abbott and DexCom settle glucose monitor patent disputes

ABT

Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement

Dec 19, 2024, 8:30 AM EST - 6 months ago

Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement

Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels

Dec 17, 2024, 9:00 AM EST - 6 months ago

Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

Dec 17, 2024, 9:00 AM EST - 6 months ago

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM

Dec 17, 2024, 8:00 AM EST - 6 months ago

Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM

DexCom: Brighter 2025 From Stelo Ramp

Dec 10, 2024, 3:18 PM EST - 6 months ago

DexCom: Brighter 2025 From Stelo Ramp

11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs

Dec 5, 2024, 7:00 AM EST - 7 months ago

11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs

ADBE AMZN BXP CMCSA GPN ILMN PFE

Tomyw
Tomyw Jun. 20 at 7:31 PM
$DXCM https://youtu.be/mwHurP6XObw
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 6:18 PM
🚀 $DXCM shares have gained 18.6% QTD, outperforming the industry decline — what's supporting the momentum? 🔹 Record new patient growth & strategic initiatives 🔹 Expansion in reimbursement coverage for non-insulin T2D 🔹 Launch of 15-Day G7 system & strong commercial execution Discover the full story here 👉 https://www.zacks.com/commentary/2519590/dxcms-access-gains-and-operational-strength-offset-margin-pressures?cid=sm-stocktwits-2-2519590-body&ADID=SYND_STOCKTWITS_TWEET_2_2519590_BODY
0 · Reply
Chrisdamelio
Chrisdamelio Jun. 20 at 5:31 PM
$DXCM should be at 100. This is bologna
1 · Reply
Chrisdamelio
Chrisdamelio Jun. 20 at 5:12 PM
$DXCM come on this is no brainer. Why does it keep going down.
1 · Reply
Chrisdamelio
Chrisdamelio Jun. 20 at 5:12 PM
$DXCM
0 · Reply
roejohn
roejohn Jun. 20 at 3:08 PM
$DXCM Dexcom did its job while it was technologically OK but now it is passé. can you imagine their product actually it’s interference with acetaminophen a common over-the-counter item, vitamin C and who knows what other OTC products are problem with Dexcom ? There are just too many contraindications with Dexcom versus the newest technology by $SENS , Eversense 365 is the hottest product to accurately monitor glucose and ketones and may be used with a pump !! check it out
2 · Reply
clan
clan Jun. 20 at 12:52 PM
$DXCM should partner with $MNKD for best Time In Range [TIR].
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 12:22 PM
$DXCM’s patient growth is surging — but is it enough? Record Type 2 diabetes access gains and strong operations are driving growth, but margin pressure and FDA scrutiny are big headwinds. Full breakdown here 👉 https://www.zacks.com/stock/news/2519590/dxcms-access-gains-and-operational-strength-offset-margin-pressures?cid=sm-stocktwits-2-2519590-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2519590_TEASER
0 · Reply
Tomyw
Tomyw Jun. 19 at 11:56 PM
$DXCM …… https://www.eversensecgm.com/eversense-365/?utm_source=facebook&utm_medium=paidsocial&utm_campaign=conversion_prospectingworkableleads_365_dtc_us&utm_content=product_allfeatures_imagetext_1v36_insulin&utm_term=lal_highrated_crm&fbclid=IwQ0xDSwLBgndleHRuA2FlbQEwAGFkaWQBqyI4CuyXdgEeAM78zyw1UFI5dMhHwSzbuuS6XEMGLzsbY3IjyZKF3qY8o4g5d6AlM0MIY9k_aem_4_pPEwsrHC7xgpK8JuekHg&utm_id=120212428326440502 …….
0 · Reply
CelestialIronMan
CelestialIronMan Jun. 19 at 5:39 PM
$SANA There is no way $LLY $NVO $DXCM $PODD are going to allow us to disrupt T1D treatments out of existence without participation. Once again ask your favorite AI what the HIP platform can be applied too! If we have to actually throw the possibilities of cures out in the public domain to force big pharma to partner and license so be it. But there is no way the company can make it through clinical trials to approval in its current form for anything. Go look up the process, typically 1000 patients over years, with some exceptions for gene therapies, rare diseases, the number of beneficiaries and efficacy can speed it up. We’d be bankrupt, bought off the scrap heap. Better to offer HIP, a working MSCB and targeted delivery tech, all of which we have or are developing than to actually make cures and incur the wrath of the big pharma machinery!
1 · Reply
Punpire
Punpire Jun. 19 at 12:49 AM
$SENS This seems kind of bad for $DXCM , it would be nice if Tim Goodnow and Brian Hansen could spend money on real marketing and reach some of the people affected by this.
0 · Reply
Angiesix
Angiesix Jun. 17 at 8:44 PM
$KNW Stock should be priced about $13-14 with their BTC value on the balance sheet included. Now let BTC drop 50% this year/next in order to go bullish in 2027 or so, the stock should be trading at $7 the least. Without a product. When they release their product, this is a first to market product, billion dollar market to capture. $DXCM $ABT doesn't like competition and funds already showed what's going on ($DXCM 📉)
2 · Reply
StockHunter75
StockHunter75 Jun. 17 at 7:20 PM
$DXCM Bullish
0 · Reply
DiamondCapital
DiamondCapital Jun. 17 at 2:36 PM
$ADHC Quick DD https://x.com/stockpicksnyc/status/1934981580092482031?s=46 •Market cap $3M •GlucoGuard, diabetes medical device •Partnership with $DXCM, a $32B company •FDA Breakthrough device, positive review by FDA, pending decision •Hedgefund backing •Analyst coverage on a OTC •Impressive team, Bill Colone & former FDA official Stephen Weber In-depth research DD video by SuperRobotInvestments published on June 15th, link to video: https://www.youtube.com/watch?v=dLK26Nxq4fM ADHC Analyst report issued by Harbinger Research dated June 2, 2025 with a “Strong Speculative Buy Rating" with a price target of .012 or $43M valuation Link to the research report: https://d1io3yog0oux5.cloudfront.net/harbingerresearch/media/cf29499818e4263671232f93c2967e52.pdf By Brian R. Connell, CFA Senior Research Analyst | Harbinger Research More DD attached below (FULL DD THREAD) Just tap the attached post and repeat https://x.com/stockpicksnyc/status/1934981580092482031?s=46
1 · Reply
StockHunter75
StockHunter75 Jun. 17 at 11:12 AM
$DXCM load up she's poised to rip.
0 · Reply
IN0V8
IN0V8 Jun. 16 at 8:40 PM
$DXCM Buying opportunity Truist Securities initiates coverage with buy rating Truist Securities initiates coverage with price target $102
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 4:09 PM
Truist Securities has updated their rating for DexCom ( $DXCM ) to Buy with a price target of 102.
0 · Reply
Punpire
Punpire Jun. 16 at 2:31 PM
$SENS Interesting listen on the $DXCM G7 failures. A lot of comments from users that have switched to other CGM's. https://youtu.be/-uspQT3sG-0?si=aOP6chejMfUKyX0x
0 · Reply
Richland_2019
Richland_2019 Jun. 16 at 1:11 PM
$DXCM well, as a shareholder and consumer, I am not happy with their supply chain issues for CGM. After a week, they still can’t give me a ship date!
0 · Reply
zoey1970
zoey1970 Jun. 13 at 3:23 PM
$DXCM $SENS $PODD $ARM $TSM
0 · Reply
roejohn
roejohn Jun. 13 at 2:22 PM
$DXCM So you get 366 days of freedom of motion and more accurate reading . Get out of the past SEND is FDA approved and covered by insurance .. move forward !!
0 · Reply
dlp02446
dlp02446 Jun. 13 at 2:05 PM
$DXCM $35 or $50?
0 · Reply